U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H10ClF4NO2
Molecular Weight 359.703
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLINDOKALNER

SMILES

COC1=CC=C(Cl)C=C1[C@]2(F)C(=O)NC3=C2C=CC(=C3)C(F)(F)F

InChI

InChIKey=ULYONBAOIMCNEH-HNNXBMFYSA-N
InChI=1S/C16H10ClF4NO2/c1-24-13-5-3-9(17)7-11(13)15(18)10-4-2-8(16(19,20)21)6-12(10)22-14(15)23/h2-7H,1H3,(H,22,23)/t15-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12481191

Flindokalner (BMS 204352; MaxiPost™) is a neuroprotective agent with potential in the treatment of stroke developed by Bristol-Myers Squibb. Flindokalner is a potent and effective opener of two important subtypes of neuronal potassium channels, the calcium-activated, big-conductance potassium channels (K(Ca) channels) and voltage-dependent, non-inactivating potassium channels known as KCNQ channels. Flindokalner significantly reduced cortical infarct volume in a animal models of stroke. Flindokalner failed to show superior efficacy in acute stroke patients compared to placebo in a Phase III study.

CNS Activity

CNS Active
3913
Curator's Comment: Flindokalner (BMS 204352; MaxiPost™) is brain penetrant and active (stroke neuroprotection and anxiolytic) in rodents https://www.ncbi.nlm.nih.gov/pubmed/12214322 https://www.ncbi.nlm.nih.gov/pubmed/11283675 https://www.ncbi.nlm.nih.gov/pubmed/15814569 But Flindokalner is failed to show efficacy in acute stroke patients compared to placebo in a Phase III study. https://www.ncbi.nlm.nih.gov/pubmed/12481191

Originator

Bristol-Myers Squibb
145
Curator's Comment: # Bristol-Myers Squibb

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Opener
34
 352.0 nM [EC50]
Opener
34
 2.4 µM [EC50]
Opener
34
 2.4 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
121 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15502007
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLINDOKALNER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
184 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15502007
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLINDOKALNER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15502007
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLINDOKALNER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.38%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11745906
FLINDOKALNER plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 2 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12481191
Page: p.359
unhealthy, ADULT
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/12481191
Page: p.359
Sources:
https://pubmed.ncbi.nlm.nih.gov/12481191
Page: p.359
10 mg single, intravenous
Studied dose
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15502007
Page: p.86
healthy, ADULT
n = 8
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/15502007
Page: p.86
Disc. AE: Taste disturbance...
AEs leading to
discontinuation/dose reduction:
Taste disturbance (12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15502007
Page: p.86
AEs

AEs

AESignificanceDosePopulation
Taste disturbance 12.5%
Disc. AE
10 mg single, intravenous
Studied dose
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15502007
Page: p.86
healthy, ADULT
n = 8
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/15502007
Page: p.86
Sourcing

Sourcing

Vendor/AggregatorIDURL
ApexBio Technology
B7722
https://www.apexbt.com/catalogsearch/result/?q=B7722
Axon MedChem
1112
https://www.axonmedchem.com/product/1112
Axon MedChem
1308
https://www.axonmedchem.com/product/1308
BLD Pharm
BD317814
http://www.bldpharm.com/search/Search.html?keyword=BD317814
BOC Sciences
187523-35-9
http://www.bocsci.com/description.asp?cas=187523-35-9
Chem Scene
CS-0029243
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0029243
MedChem Express
HY-108584
https://www.medchemexpress.com/search.html?q=HY-108584&ft=&fa=&fp=
MolPort
MolPort-035-765-895
https://www.molport.com/shop/molecule-link/MolPort-035-765-895
Molnova
M12907
https://www.molnova.com/en/serch-list.html?keywords=M12907
MuseChem
R036286
https://www.musechem.com/product/R036286.html
Tocris
4949
https://www.tocris.com/search.php?Type=QuickSearch&Value=4949
Toronto Research Chemicals
B595920
https://www.trc-canada.com/product-detail/?CatNum=B595920
Toronto Research Chemicals
B596030
https://www.trc-canada.com/product-detail/?CatNum=B596030
eMolecules
36366916
https://orderbb.emolecules.com/search/#?query=36366916
eMolecules
36367019
https://orderbb.emolecules.com/search/#?query=36367019
mcule
MCULE-3677426981
https://mcule.com/MCULE-3677426981/
PubMed

PubMed

TitleDatePubMed
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels.
2001 Apr
KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology.
2001 Apr
BMS-204352 (Bristol Myers Squibb).
2001 Jun
Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.
2002 Feb 22
BMS-204352: a potassium channel opener developed for the treatment of stroke.
2002 Winter
Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
2009 Mar 17
Patents

Patents

06916937
1
20050203089
1
6916937
1
7169803
1
7812177
1

Sample Use Guides

In Vivo Use Guide
In healthy humans, single and multiple i.v. doses of BMS-204352 (0.001 to 0.2 mg/kg) were safe, well-tolerated and without psychomotor function effects. Multiple doses of BMS-204352 (0.1-2 mg/kg i.v.) administered within 48 h after stroke onset were well tolerated in patients in Phase II studies, designed to evaluate safety, tolerability and pharmacokinetics.
Route of Administration: Intravenous
In Vitro Use Guide
∼1-100 μM Flindokalner (BMS 204352) dose-dependently increased CK2 activity in SK-N-SH cells in the presence of TNF-α
Name Type Language
FLINDOKALNER
INN   USAN  
USAN   INN  
Official Name English
MAXIPOST
Brand Name English
BMS-204352
Code English
FLINDOKALNER [USAN]
Common Name English
(3S)-3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one
Systematic Name English
flindokalner [INN]
Common Name English
2H-INDOL-2-ONE, 3-(5-CHLORO-2-METHOXYPHENYL)-3-FLUORO-1,3-DIHYDRO-6-(TRIFLUOROMETHYL)-, (3S)-
Systematic Name English
(3S)-(+)-(5-CHLORO-2-METHOXYPHENYL)-1,3-DIHYDRO-3-FLUORO-6-(TRIFLUOROMETHYL)-2H-INDOL-2-ONE
Systematic Name English
BMS-204352-01
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 497515
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
NCI_THESAURUS C1509
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
EU-Orphan Drug EU/3/14/1334
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
Code System Code Type Description
EVMPD
SUB195646
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID70870176
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
CAS
187523-35-9
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
NCI_THESAURUS
C76778
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
FDA UNII
J57O328W4W
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
INN
8182
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
USAN
MM-39
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
SMS_ID
100000181839
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL266510
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
PUBCHEM
214350
Created by admin on Fri Dec 15 15:46:32 GMT 2023 , Edited by admin on Fri Dec 15 15:46:32 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FLINDOKALNER
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966